Literature DB >> 1505910

A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies.

A J Demetris1, K Nakamura, A Yagihashi, Y Iwaki, S Takaya, G G Hartman, N Murase, O Bronsther, R Manez, J J Fung.   

Abstract

Twenty-six adult patients with preformed IgG donor lymphocytotoxic antibodies received primary liver allografts under FK 506 immunosuppression. The effect of the crossmatch-positive state on early graft function and on the immunopathological and histopathological findings was compared with that of 52 crossmatch-negative control recipients. The presensitized (crossmatch-positive) patients had prolongation of early graft dysfunction, underwent more clinically indicated biopsies and had a higher incidence of cellular rejection, both overall (p less than 0.05) and within 10 days of transplantation (p less than 0.01). They also had a higher incidence of graft failure in the first 180 days (p less than 0.01). Hyperacute rejection with necrotizing or neutrophilic arteritis was not seen in the crossmatch-positive grafts. However, histological findings associated with presensitization included platelet margination in central veins and sinusoids in biopsy specimens 60 to 90 min after graft revascularization. Later biopsy specimens had neutrophilic portal venulitis followed by cholangiolar proliferation, acute cholangiolitis and centrilobular hepatocyte swelling that mimicked preservation injury, endothelial activation of arteries with medial changes and relapsing episodes of acute cellular rejection. These clinicopathological observations suggest that lymphocytotoxic antibodies can have a deleterious effect on liver allograft function and survival, even if they do not precipitate immediate or hyperacute rejection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1505910      PMCID: PMC2956418          DOI: 10.1002/hep.1840160310

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  37 in total

1.  Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1.

Authors:  S Takaya; Y Iwaki; T E Starzl
Journal:  Transplantation       Date:  1992-11       Impact factor: 4.939

2.  Relationship between the liver and lymphocytotoxic alloantibodies in inbred rats. Specific absorption by nonparenchymal liver cells.

Authors:  J Gugenheim; B Le Thai; P Rouger; M Gigou; P Gane; M C Vial; B Charpentier; M Reynes; H Bismuth
Journal:  Transplantation       Date:  1988-02       Impact factor: 4.939

3.  Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells.

Authors:  F Kissmeyer-Nielsen; S Olsen; V P Petersen; O Fjeldborg
Journal:  Lancet       Date:  1966-09-24       Impact factor: 79.321

4.  "Hyperacute" renal-homograft rejection in man.

Authors:  G M Williams; D M Hume; R P Hudson; P J Morris; K Kano; F Milgrom
Journal:  N Engl J Med       Date:  1968-09-19       Impact factor: 91.245

5.  A primate model of hyperacute renal allograft rejection.

Authors:  G J Busch; A C Martins; N K Hollenberg; R E Wilson; R W Colman
Journal:  Am J Pathol       Date:  1975-04       Impact factor: 4.307

6.  Orthotopic liver transplantation: a pathological study of 63 serial liver biopsies from 17 patients with special reference to the diagnostic features and natural history of rejection.

Authors:  D C Snover; R K Sibley; D K Freese; H L Sharp; J R Bloomer; J S Najarian; N L Ascher
Journal:  Hepatology       Date:  1984 Nov-Dec       Impact factor: 17.425

7.  Histopathology of serial graft biopsies from liver transplant recipients.

Authors:  H F Eggink; N Hofstee; C H Gips; R A Krom; H J Houthoff
Journal:  Am J Pathol       Date:  1984-01       Impact factor: 4.307

8.  Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys.

Authors:  Thomas E Starzl; Anthony J Demetris; Satoru Todo; Yoogoo Kang; Andreas Tzakis; Rene Duquesnoy; Leonard Makowka; Barbara Banner; Waldo Concepcion; Kendrick A Porter
Journal:  Clin Transplant       Date:  1989       Impact factor: 2.863

9.  Evidence for an immune response to HLA class I antigens in the vanishing-bileduct syndrome after liver transplantation.

Authors:  P T Donaldson; G J Alexander; J O'Grady; J Neuberger; B Portmann; M Thick; H Davis; R Y Calne; R Williams
Journal:  Lancet       Date:  1987-04-25       Impact factor: 79.321

10.  Hyperacute renal allograft rejection in the rabbit. Vasoconstriction demonstrated by microangiography.

Authors:  Y Terada; A Ueno
Journal:  Transplantation       Date:  1983-03       Impact factor: 4.939

View more
  28 in total

1.  Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts.

Authors:  S Takaya; A Jain; A Yagihashi; K Nakamura; M Kobayashi; K Takeuchi; S Suzuki; Y Iwaki; A J Demetris; S Todo; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1999-08       Impact factor: 1.066

2.  The impact of positive T-cell lymphocytotoxic crossmatch on intestinal allograft rejection and survival.

Authors:  G Bond; J Reyes; G Mazariegos; T Wu; N Schaefer; J Demetris; J J Fung; T E Starzl; K Abu-Elmagd
Journal:  Transplant Proc       Date:  2000-09       Impact factor: 1.066

3.  Preformed lymphocytotoxic antibodies: the effects of class, titer and specificity on liver vs. heart allografts.

Authors:  T Furuya; N Murase; K Nakamura; J Woo; S Todo; A J Demetris; T E Starzl
Journal:  Hepatology       Date:  1992-12       Impact factor: 17.425

4.  Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin.

Authors:  L A Valdivia; A J Demetris; J J Fung; S Celli; N Murase; T E Starzl
Journal:  Transplantation       Date:  1993-03       Impact factor: 4.939

5.  Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch.

Authors:  H R Doyle; I R Marino; F Morelli; C Doria; L Aldrighetti; J McMichael; J Martell; T Gayowski; T E Starzl
Journal:  Ann Surg       Date:  1996-08       Impact factor: 12.969

Review 6.  Enhancing the Value of Histopathological Assessment of Allograft Biopsy Monitoring.

Authors:  Michelle A Wood-Trageser; Andrew J Lesniak; Anthony J Demetris
Journal:  Transplantation       Date:  2019-07       Impact factor: 4.939

7.  The Future of Xenotransplantation.

Authors:  Thomas E Starzl
Journal:  Ann Surg       Date:  1992-10-01       Impact factor: 12.969

8.  The role of donor-specific HLA alloantibodies in liver transplantation.

Authors:  J G O'Leary; A J Demetris; L S Friedman; H M Gebel; P F Halloran; A D Kirk; S J Knechtle; S V McDiarmid; A Shaked; P I Terasaki; K J Tinckam; S J Tomlanovich; K J Wood; E S Woodle; A A Zachary; G B Klintmalm
Journal:  Am J Transplant       Date:  2014-03-01       Impact factor: 8.086

Review 9.  Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation.

Authors:  Antonio Cuadrado; David San Segundo; Marcos López-Hoyos; Javier Crespo; Emilio Fábrega
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

10.  Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies.

Authors:  S L Saidman; R J Duquesnoy; A J Demetris; J McCauley; H Ramos; G Mazariegos; R Shapiro; T E Starzl; J J Fung
Journal:  Transpl Immunol       Date:  1994       Impact factor: 1.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.